Regencell Bioscience (NASDAQ:RGC) Shares Down 7.3% - Should You Sell?
2026-03-30 15:14:56 ET
Regencell Bioscience Holdings Limited ( NASDAQ:RGC – Get Free Report )’s stock price dropped 7.3% during mid-day trading on Monday . The stock traded as low as $23.60 and last traded at $23.7890. Approximately 27,765 shares traded hands during mid-day trading, a decline of 93% from the average daily volume of 413,495 shares. The stock had previously closed at $25.67.
Analyst Upgrades and Downgrades
Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Regencell Bioscience in a research report on Friday. One analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, Regencell Bioscience presently has an average rating of “Sell”.
View Our Latest Stock Report on RGC
Regencell Bioscience Stock Down 8.1%
The company’s fifty day moving average price is $26.92 and its 200-day moving average price is $21.43.
Institutional Inflows and Outflows
Hedge funds have recently modified their holdings of the business. Seven Fleet Capital Management LP purchased a new stake in shares of Regencell Bioscience in the fourth quarter worth approximately $92,000. Vident Advisory LLC boosted its holdings in Regencell Bioscience by 65.7% during the 4th quarter. Vident Advisory LLC now owns 29,934 shares of the company’s stock valued at $629,000 after acquiring an additional 11,866 shares during the period. Hudson Bay Capital Management LP bought a new position in Regencell Bioscience in the 4th quarter valued at $275,000. XTX Topco Ltd bought a new position in Regencell Bioscience in the 3rd quarter valued at $598,000. Finally, Squarepoint Ops LLC purchased a new stake in Regencell Bioscience in the second quarter worth $1,701,000. Institutional investors own 0.13% of the company’s stock.
Regencell Bioscience Company Profile
( Get Free Report )
Regencell Bioscience Holdings Limited operates a Traditional Chinese medicine (TCM) bioscience company. It focuses on the research, development, and commercialization of TCM for the treatment of neurocognitive disorders and degeneration, primarily attention deficit hyperactivity disorder and autism spectrum disorder. The company was incorporated in 2014 and is headquartered in Causeway Bay, Hong Kong.
Further Reading
NASDAQ: RGC
RGC Trading
-4.24% G/L:
$22.58 Last:
56,748 Volume:
$23.66 Open:
